Feedback plc (LON:FDBK), the medical imaging software company, has identified some enhancements to its TexRAD Lung product that will delay the granting of a CE mark.
The company had previously expected the CE mark by the end of this month but this will now not happen after the company came up with several enhancements that will improve the performance of this version of TexRAD.
Feedback said the introduction of these modifications will result in a delay of several weeks before the CE mark for TexRAD Lung is obtained.
Medical devices are required to have a CE mark before they can legally be sold in the European Union. Feedback is obviously confident of obtaining the mark, because it said it does not expect the delay to have any effect on the commercial negotiations that are underway in respect of TexRAD.
In particular, Feedback stressed the delay would have no effect on the schedule of the deal announced at the end of March (see below).
READ Feedback surges after it pencils TexRAD Lung deal
WATCH chairman Dr Alastair Riddell talk about the TexRAD Lung deal and others in the pipeline
Feedback’s subsidiary, Cambridge Computed Imaging, remains in discussions with other leading imaging companies as it attempts to widen the range of potential routes to market for clinical versions of TexRAD.